权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

SBIR Phase I: Novel Biosensor for Monitoring of Theophylline using Personal Glucose Meter

SBIR 第一阶段：使用个人血糖仪监测茶碱的新型生物传感器

基本信息

批准号：
1215421
负责人：
Tian Lan
金额：
$ 15万
依托单位：
GlucoSentient, Inc.
依托单位国家：
美国
项目类别：
Standard Grant
财政年份：
2012
资助国家：
美国
起止时间：
2012-07-01 至 2013-06-30
项目状态：
已结题

来源：
https://www.nsf.gov/awardsearch/showAward?AWD_ID=1215421&HistoricalAwards=false
关键词：
SBIR Phase Novel Biosensor Monitoring

项目摘要

This Small Business Innovation Research Phase I project aims to develop a new technology to utilize ubiquitous personal glucose meters (PGMs) for inexpensive and convenient at-home tests of the drug theophylline. Theophylline has been widely used to treat asthma and chronic obstructive pulmonary diseases. It has a narrow effective range and adverse side effects when overdosed, thus frequent test of plasma theophylline are recommended for patients using this drug. The technology in this project converts plasma theophylline into glucose quantitatively by a theophylline-triggered enzymatic reaction, so theophylline is monitored through glucose detection by inexpensive and convenient PGMs.The broader commercial impacts of this research are more convenience and lower costs for therapeutic drug monitoring. In the era of personalized medicine, the dosage of a drug is as important as the drug itself. Many other drugs are similar to theophylline in terms of narrow effective ranges and adverse side effects when overdosed. Currently, testing levels for these types of drugs requires hospital visits and blood draws, which are inconvenient, time consuming and costly. The proposed innovation here can also be translated to measure other drugs' concentrations more simply, quickly and cheaply. The innovation proposed here can be used for drug monitoring in general which will have great impact on the quality and affordability of healthcare worldwide.

这个小企业创新研究第一阶段项目旨在开发一种新技术，利用无处不在的个人血糖仪（PGMs）进行药物茶碱的廉价和方便的家庭测试。茶碱已被广泛用于治疗哮喘和慢性阻塞性肺疾病。茶碱的有效范围较窄，过量服用会产生不良反应，因此建议对使用该药的患者经常进行血浆茶碱检测。本项目的技术通过茶碱触发的酶促反应将血浆中的茶碱定量转化为葡萄糖，从而通过廉价且方便的PGMs检测葡萄糖来监测茶碱。本研究的更广泛的商业影响是治疗药物监测的更方便和更低的成本。在个性化医疗时代，药物的剂量与药物本身一样重要。许多其他药物在有效范围狭窄和过量时的不良副作用方面与茶碱相似。目前，检测这些类型药物的水平需要到医院就诊和抽血，这是不方便、耗时和昂贵的。这里提出的创新也可以转化为更简单，快速和廉价地测量其他药物的浓度。本文提出的创新可用于一般药物监测，这将对全球医疗保健的质量和可负担性产生重大影响。